跳至主要内容
临床试验/CTRI/2022/12/048356
CTRI/2022/12/048356已完成未知

Evaluation of Skin Safety of test product using 24 Hours Patch Test Under CompleteOcclusion on Adult Healthy Human Participants with Non-Sensitive SkinIS 4011:2018 Guidelines.

Dabur India Limited0 个研究点目标入组 26 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Voluntary men and women (preferably equal number of males and females) between 18 and
  • 2. Participants representing normal, oily, dry and combination skin type in approximately equal
  • 3. Fitzpatrick skin type III to IV.
  • 4. Having apparently healthy skin on test area.
  • 5. Willingness to discontinue the use of cleansing and/or cosmetic products in the application
  • areas during the course of the trial
  • 6. Cooperating, informed of the need and duration of the examinations, and ready to comply
  • with protocol procedures.
  • 7. Willing to give written informed consent to participate in the trial after informing all
  • information concerning the trial procedures and trial objectives.
  • 8. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course
  • of the trial.
  • 9. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.:
  • exercise, saunaâ?¦), during the course of the trial.
  • 10. Should be able to read and write (in English, Hindi, or local language).
  • 11. Ready to wear loose cotton clothes
  • 12. Having valid proof of identity and age.
  • 13. Subject having not participated in another trial in the past one month.

排除标准

  • 1. Pregnancy (by history) and lactating women.
  • 2. Scars, excessive terminal hair, or tattoo on the studied area.
  • 3. A participant who the Investigator feels will not be compliant with trial requirements
  • 4. Dermatological infection/pathology on the level of studied area.
  • 5. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).
  • 6. Any clinically significant systemic or cutaneous disease, which may interfere with trial
  • procedures.
  • 7. Chronic illness which may influence the outcome of the trial.
  • 8. Participants on any medical treatment either systemic or topical which may interfere with the
  • performance of the trial (presently or in the past 1 month).
  • 9. Participant in an exclusion period or participating in another food, cosmetic or therapeutic

研究者

相似试验